Dermapharm Holding Se · XETR:DMP
Dermapharm — Q1 2023 Earnings Presentation
16 slides from Dermapharm's earnings presentation, May 15, 2023
Slide 1: Investors' and Analysts' Conference Call Q1 2023
INVESTORS’ AND ANALYSTS’ CONFERENCE CALL Q1 2023 Grünwald, 15 May 2023
Slide 2: Agenda Q1 2023
AGENDA Q1 2023 1. Financial figures Q1 2023 2. Outlook 2023 3. Q&A 2
Slide 3: Financial figures Q1 2023
Financial figures Q1 2023 oN a
Slide 4: Dermapharm Group
Dermapharm Group Continuous growth, with strong contribution of newest acquisition Total Revenue EBITDA1 Significant revenue growth of 37.8% to €m €m, adjusted €319.1m, driven by +37.8% 33.2% newly acquired Arkopharma Group (Jan. YoY EBITDA 2023) 319.1 Margin 32.4% “branded pharmaceuticals” prod
Slide 5: Branded pharmaceuticals and other healthcare products
Branded pharmaceuticals and other healthcare products Strong organic growth and favourable product mix Revenue EBITDA1 Strong revenue growth of 10.8% to €m €m, adjusted +10.8% €161.4m, due to 50.3% YoY EBITDA high demand for classic “branded 161.4 pharmaceuticals” products especially in Margin der
Slide 6: Herbal extracts
Herbal extracts First time consolidation of Arkopharma and growing revenue of the existing business Revenue EBITDA1 Significant revenue growth by 256.6% to €m €m, adjusted €91.3m, driven by +256.6% 26.3% initial consideration of Arkopharma Group YoY 91.3 EBITDA Margin organically growing Euromed
Slide 7: Parallel import business
Parallel import business Combination of favourable market trend, partially reduced purchase prices and efficiency improvements Revenue EBITDA Revenues increased by 9.9% to €66.4m, €m €m, adjusted driven by +9.9% 2.7% favourable general PI market trend YoY 66.4 EBITDA Margin growing OTC and narco
Slide 8: Earnings before tax (Group EBT)
Earnings before tax (Group EBT) Improved EBITDA result drives EBT growth despite higher interest expenses Earnings before tax (EBT)1 Unadjusted EBT increased by 21.6% to €m €69.8m translating to a margin of 21.9% 24.8% Lower EBT profitability mainly driven by EBT 21.9% Margin Increased (negative
Slide 9: New syndicated loan
New syndicated loan combines long-term financing stability with high flexibility Key Facts Facilities €m Volume €1,050 m (+ Incremental Option €200m) 1,200 Maturity 15 December 2027 1,000 200 800 200 Lender 6 banks with strong credit rating 600 Facilities Term and revolving facilities 400 650 Repaym
Slide 10: Strong cash flows and cash conversion
Strong cash flows and cash conversion High operating cash conversion of 69.8% with large investments to fund future growth Cash flow and cash conversion1 CF from operating activities in 3M 2023 €m and in % of Group EBITDA mainly influenced by increased EBITDA result and a slower working capital bu
Slide 11: Balance Sheet of Dermapharm Group
Balance Sheet of Dermapharm Group Balance sheet as of 31 March 2023 Total assets increased to €2,168m €m (31 December 2022: €1,413m) Increase of non-current assets 2,168 2,168 (€1,492m; 31 December 2022: €879m) and higher current assets (€676m; Equity 31 December 2022: €534m) Equity number inc
Slide 12: Outlook 2023
1 ia - ii s o> 2 Outlook 2023 T>- Clif. a.
Slide 13: Outlook 2023
Outlook 2023 Growth rates are returning to a long-term sustainable level after successful years impacted by exceptional results from the vaccine production Revenue growth is based on organic growth supported by new launches of in- house developments and initial synergies, especially from the conti
Slide 14: Q&A
3 Q&A Image: Günther Fotodesign Dermapharm PPT Master 2022 14
Slide 15: Disclaimer
Disclaimer This publication includes statements, estimates, opinions and projections with respect to the anticipated future performance of Dermapharm Holding SE (together with its consolidated subsidiaries, “Dermapharm”) and such statements, estimates, opinions and projections (“Forward-Looking Stat
Slide 16: For information, please contact
For information, please contact Britta Hamberger Investor Relations & Corporate Communications Dermapharm Holding SE E-Mail: ir@dermapharm.com Phone: +49 (0) 89 641 86 233 Dermapharm FY 2021 16